Baseline cardiopulmonary function as an independent prognostic factor for survival of inoperable non-small-cell lung cancer after concurrent chemoradiotherapy: a single-center analysis of 161 cases.

摘要

PURPOSE: Little is known about the effects of cardiopulmonary function on the prognosis of concurrent chemoradiotherapy in patients with inoperable non-small-cell lung cancer (NSCLC). METHODS AND MATERIALS: A retrospective analysis of the effects of tumor- and patient-related factors and parameters of cardiopulmonary function and heart morphology on the feasibility, toxicity, and prognosis was performed. RESULTS: Cardiopulmonary function had no effect on the toxicity or feasibility of treatment; effects on survival were observed in the univariate analysis. Median survival varied as follows: cardiac function: 13.0 +/- 1.6 months for left ventricular ejection fraction (LVEF) > 50% vs. 10.0 +/- 1.9 months for LVEF /= 60%, forced expiratory volume in 1 s >/= 80%, and diffusing capacity of the lung for carbon monoxide (DLCO) >/=60%) vs. 14.0 +/- 1.5 months for one or two function deficits vs. 8.0 +/- 1.5 months for three lung function deficits (p = 0.001); T stage: 19.0 +/- 3.1 months for rcT0/cT1/cT2 vs. 12.0 +/- 0.8 months for cT3/cT4 (p = 0.039); and age: 11.0 +/- 1.5 months for <60 years vs. 18.0 +/- 2.5 months for 60-69 years vs. 12.0 +/- 1.2 months for >/=70 years (p = 0.008). Prognostic factors identified in the multivariate analysis were LVEF